CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi

Cancer Research and Treatment. 2018;50(2):398-404. Published online 2017 May 10 DOI: https://doi.org/10.4143/crt.2017.074

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi

Cancer Research and Treatment. 2018;50(2):398-404

Link1

Link2 Link3

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Khaldoun Almhanna, David Wright, Teresa Macarulla Mercade, Jean-Luc Van Laethem, Antonio Cubillo Gracian, Carmen Guillen-Ponce, Jason Faris, Carolina Muriel Lopez, Richard A. Hubner, Johanna Bendell, Alain Bols, Jaime Feliu, Naureen Starling, Peter Enzinger, Devalingham Mahalingham, Wells Messersmith, Huyuan Yang, Adedigbo Fasanmade, Hadi Danaee, Thea Kalebic

Investigational New Drugs. 2017;35(5):634-641

Link1 Link2

Link3

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

Khaldoun Almhanna, Maria Luisa Limon Miron, David Wright, Antonio Cubillo Gracian, Richard A. Hubner, Jean-Luc Van Laethem, Carolina Muriel López, Maria Alsina, Frederico Longo Muñoz, Johanna Bendell, Irfan Firdaus, Wells Messersmith, Zhan Ye, Adedigbo A. Fasanmade, Hadi Danaee, Thea Kalebic

Investigational New Drugs. 2017;35(2):235-241

Link1

Link2 Link3

Photodynamic therapy of non-resectable cholangio carcinoma — A randomized prospective study — First results

Gastrointestinal Endoscopy. 2001;53(5):AB85

Link1 Link2

Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study

Rosamund J Wilson, Beverly Jones, Claudio Marelli

SAGE Open Medicine. 2018;6:205031211878616

Link1 Link2 Link3

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

J.T. Thigpen

Yearbook of Oncology. 2010;2010:26-27

Link1 Link2

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Jairo A. Garcia, Lewis R. Roberts

Journal of Hepatology. 2012;56(2):486-487

Link1 Link2

Dysport® for the treatment of myofascial back pain: Results from an open-label, Phase II, randomized, multicenter, dose-ranging study

Gerhard H.H. Müller-Schwefe, Michael A. Überall

Scandinavian Journal of Pain. 2011;2(1):25-33

Link1 Link2 Link3 Link4

A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer

Peter M. Ellis, Quincy S. Chu, Natasha Leighl, Scott A. Laurie, Holger Fritsch, Birgit Gaschler-Markefski, Steve Gyorffy, Gerd Munzert

Clinical Lung Cancer. 2013;14(1):19-27

Link1 Link2

Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study

Kaoru Kubota, Seiji Niho, Sotaro Enatsu, Yoshihiro Nambu, Yutaka Nishiwaki, Nagahiro Saijo, Masahiro Fukuoka

Journal of Thoracic Oncology. 2009;4(12):1530-1536

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.